| Literature DB >> 29775297 |
Mimi L Quan1, Donald J P Pinto1, Joanne M Smallheer1, William R Ewing1, Karen A Rossi1, Joseph M Luettgen1, Dietmar A Seiffert1, Ruth R Wexler1.
Abstract
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29775297 DOI： 10.1021/acs.jmedchem.8b00173
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446